2025-18651Notice

FDA Drafts Clever Trials for Rare Gene Therapy Cures

Published Date: 9/25/2025

Notice

Summary

The FDA just dropped a draft guide to help companies testing cell and gene therapies for rare diseases. It shows smart ways to design clinical trials that speed up getting these treatments approved without cutting corners. If you’re developing these therapies, this could save time and money while making sure the treatments really work.

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

Designs and endpoints to support licensure

The draft guidance describes FDA requirements and provides considerations for using various clinical trial designs and endpoints to generate clinical evidence that supports product licensure. It is aimed at helping sponsors plan how to collect the evidence the FDA will consider for approval.

Promotes innovative designs to expedite development

The guidance recommends that sponsors developing CGTs for small populations leverage innovative trial designs to simultaneously expedite drug development and generate the data necessary to demonstrate substantial evidence of effectiveness. The recommendation is targeted to sponsors of CGT products intended for small populations.

Draft guidance for CGT in rare diseases

If you sponsor cell or gene therapy (CGT) trials for diseases that meet the rare disease definition under section 526(a)(2) (21 U.S.C. 360bb(a)(2)), the FDA released a draft guidance titled "Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations." The document is intended for sponsors planning trials of CGT products in small populations.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Comments Due
9/25/2025
11/24/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in